Medicilon DMPK & Bioanalysis Services (Download)
Facebook LinkedIn Fill out the form below to download this content.
Medicilon—High Quality Integrated Drug R&D Services (Download)
Facebook LinkedIn Fill out the form below to download this content.
Medicilon Large Animal Pharmacodynamic Research Service Platform (Download)
Facebook LinkedIn Fill out the form below to download this content.
Medicilon Supports Partner Nuoyuan Medical Equipment Co., Ltd. in Securing FDA IND Approval for Class 1 Innovation Drug Pemefolacianine
2025-01-07 On December 20, Nanjing Nuoyuan Medical Devices Co., Ltd. (“Nuoyuan Medical”) received FDA approval for an IND application for Pemefolacianine, an innovative Class 1 drug. This marks the first FDA IND approval for a folate receptor-targeted imaging agent developed in China, following Cytalux (OTL-38), the world’s first FDA-approved agent of its kind. Pemefolacianine has […]
A Decade of Collaboration: Medicilon Supports SinoRDA in Achieving Approval for Linaprazan Glurate
2025-01-02 On December 3, Shanghai SinoRDA Science and Technology Co., Ltd., a subsidiary of Guizhou SinoRDA Biotechnology Co., Ltd. (SinoRDA), secured approval from the National Medical Products Administration for its Linaprazan Glurate capsules. This milestone drug, a Category 1 chemical medication, is designed to treat reflux esophagitis. Medicilon, a trusted partner of SinoRDA for over a […]
Medicilon Supports Strategic Partner CGeneTech in Achieving Approval for Next-Generation DPP-4 Inhibitor
2025-01-02 CGeneTech Biopharmaceutical Technology (Suzhou) Co., Ltd. (“CGeneTech”) recently marked a significant milestone with the approval of its innovative Class 1 drug, Sentagliptin Phosphate tablets, for marketing in China. As a strategic partner, Medicilon provided comprehensive preclinical research services that complied with GLP standards, encompassing pharmacodynamics, pharmacokinetics, safety evaluations, and biomarker bioanalysis in Phase I clinical trials. Medicilon’s reliable research system—demonstrating high consistency […]
Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer
Medicilon, a leading preclinical contract research organization (CRO), has named Dr. Lilly Xu as its new Chief Technology Officer (CTO). With over 30 years of experience in preclinical drug development, Dr. Xu will lead Medicilon’s technological innovation and global expansion, strengthening its capabilities to deliver cutting-edge R&D solutions. Dr. Lilly Xu Chief Technology Officer of Medicilon […]
Medicilon Supports Partner Jemincare in Securing Clinical Approval for JM045 Sustained-Release Microspheres
2024-12-03 Recently, JM045 sustained-release microspheres, independently developed by the Institute of Innovative Pharmaceuticals under Jemincare Pharmaceutical Group, received clinical trial approval. Medicilon, as a trusted partner, provided pharmacokinetic studies and GLP-compliant safety evaluations, playing an instrumental role in advancing the drug development process. JM045: A New Hope for Prostate Cancer Patients JM045 is a gonadotropin-releasing hormone (GnRH) analog […]
Large Animal Models: Essential Tools in Disease Research
2024-12-02 Compared to rodents and non-human primates, large animal models such as dogs and miniature pigs offer unique advantages. They provide a balance between genetic, physiological, and structural similarities to humans, while maintaining relatively low experimental costs, making them invaluable in research and medical applications. These models are particularly effective in studying cardiovascular, neurological, dermatological, […]
PDXO Model: A Significant Advancement in Precision Oncology
2024-12-02 Patient-Derived Xenograft Organoids (PDXOs) are 3D organoid models derived from patient-derived xenograft (PDX) tumor tissues. Constructed using methods similar to those employed for patient-derived organoids (PDOs), PDXOs replicate the genetic, molecular, and structural features of the original tumors with exceptional accuracy. These models surpass traditional 2D cell cultures by preserving the complex internal architecture […]
